

Therapy found to reduce lipoprotein(a) levels

January 3 2020



(HealthDay)—For patients with elevated lipoprotein(a) levels and established cardiovascular disease, hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L_{RX} (APO(a)-L_{RX}) reduces

lipoprotein(a) levels, according to a study published online Jan. 1 in the *New England Journal of Medicine*.

Sotirios Tsimikas, M.D., from the Sulpizio Cardiovascular Center at the University of California, San Diego, and colleagues conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening [lipoprotein](#)(a) levels of at least 60 mg/dL. For six to 12 months, patients received either APO(a)-L_{RX} (20, 40, or 60 mg every four weeks; 20 mg every two weeks; or 20 mg every week) or saline placebo subcutaneously.

The researchers observed dose-dependent decreases in lipoprotein(a) levels, with mean decreases of 35, 56, 58, 72, and 80 percent at a dose of 20 mg every four weeks, 40 mg every four weeks, 20 mg every two weeks, 60 mg every four weeks, and 20 mg every week, respectively, compared with 6 percent for placebo. With respect to [platelet counts](#), liver and renal measures, or influenza-like symptoms, there were no significant differences between any APO(a)-L_{RX} dose and placebo. Injection-site reactions were the most common adverse events.

"Elevated levels of lipoprotein(a) are a cardiovascular risk factor for which no effective pharmacological therapy currently exists," the authors write. "In this trial, we found that APO(a)-L_{RX} provided potent reductions in levels of lipoprotein(a) in patients with [cardiovascular disease](#)."

The study was funded by Akcea Therapeutics, the manufacturer of APO(a)-L_{RX}.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: Therapy found to reduce lipoprotein(a) levels (2020, January 3) retrieved 4 May 2024 from <https://medicalxpress.com/news/2020-01-therapy-lipoproteina.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.